Neoadjuvant Camrelizumab for Triple-Negative Breast Cancer

Breast cancer is the most frequently diagnosed cancer globally and the leading cause of cancer-related deaths among women. Approximately 15% of breast cancers are classified as triple-negative breast cancer (TNBC). TNBC is characterized by the absence of the estrogen receptor, the progesterone receptor, and the human epidermal growth factor receptor 2, but it is a heterogeneous disease with varying histopathological and molecular features. In general, TNBC is more aggressive than other types of breast cancer and often gives rise to metastases. Chemotherapy forms the basis of systemic treatment. The most effective agents include taxanes, anthracyclines, platinum salts, cyclophosphamide, and capecitabine.